ORCHARD osimertinib + savolitinib interim analysis: A biomarker-directed phase II platform study in patients (pts) with advanced non-small cell lung cancer (NSCLC) whose disease has progressed on first-line (1L) osimertinib Meeting Abstract
| Authors: | Yu, H. A.; Ambrose, H.; Baik, C.; Cho, B. C.; Cocco, E.; Goldberg, S. B.; Goldman, J. W.; Kraljevic, S.; de Langen, A. J.; Okamoto, I.; Piotrowska, Z.; Pluta, M.; Powar, S.; Reguart Aransay, N.; Riess, J. W.; Le, X. |
| Abstract Title: | ORCHARD osimertinib + savolitinib interim analysis: A biomarker-directed phase II platform study in patients (pts) with advanced non-small cell lung cancer (NSCLC) whose disease has progressed on first-line (1L) osimertinib |
| Meeting Title: | ESMO Congress 2021 |
| Journal Title: | Annals of Oncology |
| Volume: | 32 |
| Issue: | Suppl. 5 |
| Meeting Dates: | 2021 Sep 16-21 |
| Meeting Location: | Virtual |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2021-09-01 |
| Start Page: | S978 |
| End Page: | S979 |
| Language: | English |
| ACCESSION: | WOS:000700527702257 |
| DOI: | 10.1016/j.annonc.2021.08.1844 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 1239P -- Source: Wos |
